Bluebird Bio

Bluebird Bio CEO Nick Leschly

The biotech: Bluebird Bio
Round: $60 million
Based: Cambridge, MA
CEO: Nick Leschly
Investors: ARCH Venture Partners, Forbion Capital Partners, RA Capital Management, Third Rock Ventures,TVM Capital, Undisclosed Investor, Undisclosed Investor

The scoop: Whatever disadvantages Bluebird may face, lack of cash isn't one of them. This most recent round brought its venture take to $110 million, making it one of the better-funded biotechs in early-stage development. Bluebird, though, is focused on rare diseases, where small studies can deliver big results. The Third Rock creation--CEO Nick Leschly was part of the Millennium mafia that booted up the venture group--has already scored proof-of-concept data for adrenoleukodystrophy, or ALD. And Leschly now has his sights set on a pivotal study for next year. Bluebird is the reincarnation of Genetix, a repurposed gene therapy company that believes the technology's time has finally come. Bluebird was named a Fierce 15 company this year.

For more:
Special Report: Bluebird Bio – 2012 Fierce 15
Bluebird adds $60M venture haul to fuel pivotal gene therapy study
Bluebird's gene therapy song attracts $30M venture round

Bluebird Bio
Read more on

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.